# Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

> **NCT01164995** · PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 24 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** MK-1775 and carboplatin

## Key facts

- **NCT ID:** NCT01164995
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2023-04
- **Final completion:** 2023-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164995, "Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01164995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*